ArticleLeukemia2026

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

Michael Y Choi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.